| Date | Form | Description | Docs | XBRL | Pages |
| 09/16/19 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 09/12/19 | DEF 14A | Definitive proxy statements |
|
46 | |
| 09/06/19 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
84 |
| 08/27/19 | 8-K | Current report filing |
|
13 | |
| 08/21/19 | 8-K | Current report filing |
|
25 | |
| 07/18/19 | 8-K | Current report filing |
|
4 | |
| 06/21/19 | EFFECT | Notice of Effectiveness |
|
1 | |
| 06/19/19 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 06/18/19 | UPLOAD | SEC-generated letter |
|
1 | |
| 06/12/19 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
39 |
Latest News & Events
Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board
Read More...Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties
Read More...Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress
Read More...